| The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation | Cardiovascular Diabetology | 2019 | 64 |
| Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia | Journal of the American College of Cardiology | 2019 | 60 |
| The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction | American Heart Journal | 2019 | 57 |
| Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials | Pharmacological Research | 2019 | 54 |
| The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions | ESC Heart Failure | 2019 | 40 |
| A new dawn for managing dyslipidemias: The era of rna-based therapies | Pharmacological Research | 2019 | 39 |
| Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study | American Heart Journal | 2019 | 39 |
| The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension | British Journal of Pharmacology | 2019 | 29 |
| Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text | Current Vascular Pharmacology | 2019 | 23 |
| Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic? | Clinical Chemistry | 2019 | 22 |
| Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia | Atherosclerosis | 2019 | 20 |
| Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement | Current Vascular Pharmacology | 2019 | 18 |
| Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study" | Journal of Clinical Lipidology | 2019 | 18 |
| Effects of sympathetic modulation in metabolic disease | Annals of the New York Academy of Sciences | 2019 | 16 |
| A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study | Journal of Clinical Lipidology | 2019 | 13 |
| Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review | Current Vascular Pharmacology | 2019 | 12 |
| Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome | Diabetic Medicine | 2019 | 11 |
| Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy | Journal of Clinical Lipidology | 2019 | 10 |
| Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies | Diabetes, Obesity and Metabolism | 2019 | 10 |
| Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration | Metabolism: Clinical and Experimental | 2019 | 8 |
| Predicting intention to participate in self-management behaviors in patients with Familial Hypercholesterolemia: A cross-national study | Social Science and Medicine | 2019 | 8 |
| Loneliness in psychotic illness and its association with cardiometabolic disorders | Schizophrenia Research | 2019 | 8 |
| Improving the detection of familial hypercholesterolaemia | Pathology | 2019 | 7 |
| Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia | Atherosclerosis | 2019 | 6 |
| Status of PCSK9 Monoclonal Antibodies in Australia | Heart Lung and Circulation | 2019 | 6 |
